Navigation Links
Alimera Sciences Reports Second Quarter 2013 Financial Results
Date:8/12/2013

ATLANTA, Aug. 12, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30, 2013.

"We began generating revenue from ILUVIEN in the second quarter of 2013 in Germany and the United Kingdom and continue to make progress in gaining market access in Germany, the United Kingdom and France," said Dan Myers, Alimera's president and chief executive officer. "The initial response has been very positive among early adopting physicians as well as patients, with some of the patients receiving an implant in both eyes."

Market Access Update ILUVIEN was launched commercially in the United Kingdom and Germany in April and May 2013, respectively, and Alimera expects to launch ILUVIEN in France in the first quarter of 2014. In addition to sales activity, Alimera is pursuing expanded reimbursement in the United Kingdom and Germany and will soon be engaged in price negotiations in France.

In the United Kingdom, the recent issuance by the Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence (NICE) of a positive Appraisal Consultation Document (ACD) on ILUVIEN is expected to lead to an Appraisal Committee meeting later in August to produce a Final Appraisal Determination (FAD). Alimera is optimistic that a FAD will be issued in September confirming the recommendation of ILUVIEN for the treatment of chronic DME in a pseudophakic population insufficiently responsive to available therapies, however there can be no assurance that NICE will accept the Appraisal Committee's recommendation.

"We are working diligently to increase the availability of ILUVIEN to patients in these countries. While the expanded reimb
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial Results
2. Alimera Sciences Reports First Quarter 2013 Financial Results
3. Alimera Sciences Secures $20 Million Debt Facility
4. Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
5. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
6. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
7. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
8. Alimera Sciences Names European Management Team
9. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
10. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
11. Ohr Pharmaceutical to Present at the Wedbush Life Sciences Management Access Conference on August 14th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 LifeNet Health plans to ... for 2015 to more than 160 people. ... for LifeNet Health,s innovative bio-implants, which are being made ... to be served. It also is a reflection of ... "The growth and success of LifeNet Health is ...
(Date:5/29/2015)... DUBLIN , May 29, 2015 ... has announced the addition of the "Surgical/Operating ... Global Forecast to 2020" report to their ... The global surgical microscopes market is poised to ... in 2014, at a CAGR of 12.3% from ...
(Date:5/29/2015)... May 29, 2015  Haemonetics Corporation (NYSE: HAE ... Operating Officer, will present at the JMP Securities Life ... on June 23 rd , 2015 at 11:30am Eastern ... Davies, presentation live via webcast at: http://wsw.com/webcast/jmp27/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2
... Ventus Medical, Inc. a privately-held medical device company ... breathing, today announced that it has received CE ... (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-b ) ... pleased to accomplish this important regulatory milestone. Receiving ...
... Cempra Pharmaceuticals today announced the appointment of David ... well as announcing an expansion of its clinical ... programs, solithromycin and TAKSTA ... significant anti-infective clinical development experience. Solithromycin ...
Cached Medicine Technology:Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 3
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... ProIntro Magnify contains 30 self-animating and minimalistic Titles including ... elegant opening title to any Final Cut Pro X ... layouts. ProIntro Magnify is created exclusively for Final Cut Pro ... Simply drag a preset into the FCPX timeline ... Inspector window then watch as ProIntro Magnify does the rest. ...
(Date:5/30/2015)... EHO offers a suite of online applications in ... ability to manage their drug-spend for the lowest cost ... has been able to compete with the big corporate ... among the giants of the industry. Since EHO launched ... it has simplified the way hospices can monitor patients ...
(Date:5/30/2015)... City of Industry, CA (PRWEB) May 30, 2015 ... of best-in-class technology and foreign travelers who experienced OGAWA ... made available in the U.S. , A leader ... decades, OGAWA is a cutting-edge designer, researcher, developer and ... for the longevity and superior craftsmanship of their products, ...
(Date:5/30/2015)... Nicole Blodgett, Vice President of Secura ... designation to further her expertise in the income ... insurance advisors, health care professionals, and financial planners ... associated with the risk and the cost with ... the latest accomplishment in Nicole's journey with Secura ...
Breaking Medicine News(10 mins):Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Secura Consultants Expands Disability Insurance Expertise 2
... glaucoma important so that treatment can be used in the ... further vision loss. Writing in a forthcoming issue of the ... in the US have analyzed and ranked the various risk ... screened at an earlier stage if they are more likely ...
... , THURSDAY, Oct. 6 (HealthDay News) -- ,Food ads have ... lessen that effect, according to a new study. It ... cartoons, with a commercial between each cartoon. Half the children ... half saw a commercial for French fries. After watching ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay News) -- A ... allows some patients to cast away the medicines meant to ... a small new study from the Stanford University School of ... and while they can greatly improve quality of life for ...
... Jenifer Goodwin HealthDay Reporter , WEDNESDAY, Oct. ... whose symptoms closely mimic autism in humans. Though ... mice in this study come closer to mirroring all ... humans, said senior study author Matthew Anderson, an assistant ...
... awarded $1.1 million to the University of Rochester Medical Center ... years has been training people in China to investigate the ... of people has developed who now are becoming rigorous researchers," ... of Psychiatry and principal investigator for the program. "It has ...
... , A Johns Hopkins Children,s Center study of young people ... that some children have a higher risk of invasive disease ... the journal Cancer , is believed to be the ... the results suggest some profound biological differences between childhood and ...
Cached Medicine News:Health News:Detecting glaucoma before it blinds 2Health News:TV Ads Whet Kids' Appetite for Junk Food 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 3Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 4Health News:Scientists Engineer Mice That Have Autism 2Health News:Scientists Engineer Mice That Have Autism 3Health News:NIH funds continued research in suicide prevention in China 2Health News:NIH funds continued research in suicide prevention in China 3Health News:NIH funds continued research in suicide prevention in China 4Health News:Invasive melanoma may be more likely in children than adults 2
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
Shoulder Subluxation Inhibitor (SSI) is an ideal bracing system to keep athletes on the field by reducing the risk of shoulder injury. The SSI is the only brace that allows TOTAL ANTERIOR RANGE OR MO...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... With just a single size, the Sierra Universal ... unique design provides the comfort and motion restriction ... you will get the right size for the ... since the single size and compact design alleviate ...
Medicine Products: